Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia.
Brabson JP, Leesang T, Yap YS, Wang J, Lam MQ, Fang B, Dolgalev I, Barbieri DA, Strippoli V, Bañuelos CP, Mohammad S, Lyon P, Chaudhry S, Donich D, Swirski A, Roberts E, Diaz I, Karl D, Dos Santos HG, Shiekhattar R, Neel BG, Nimer SD, Verdun RE, Bilbao D, Figueroa ME, Cimmino L. Brabson JP, et al. Among authors: yap ys. Cell Rep. 2023 Jan 31;42(1):112027. doi: 10.1016/j.celrep.2023.112027. Epub 2023 Jan 23. Cell Rep. 2023. PMID: 36848231 Free PMC article.
TET1 is a tumor suppressor of hematopoietic malignancy.
Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, Mullenders J, King B, Trimarchi T, Aranda-Orgilles B, Liu C, Shen S, Verma AK, Jaenisch R, Aifantis I. Cimmino L, et al. Among authors: yap ys. Nat Immunol. 2015 Jun;16(6):653-62. doi: 10.1038/ni.3148. Epub 2015 Apr 13. Nat Immunol. 2015. PMID: 25867473 Free PMC article.
Hepatic Dysfunction Caused by Consumption of a High-Fat Diet.
Soltis AR, Kennedy NJ, Xin X, Zhou F, Ficarro SB, Yap YS, Matthews BJ, Lauffenburger DA, White FM, Marto JA, Davis RJ, Fraenkel E. Soltis AR, et al. Among authors: yap ys. Cell Rep. 2017 Dec 12;21(11):3317-3328. doi: 10.1016/j.celrep.2017.11.059. Cell Rep. 2017. PMID: 29241556 Free PMC article.
Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
Chen X, Glytsou C, Zhou H, Narang S, Reyna DE, Lopez A, Sakellaropoulos T, Gong Y, Kloetgen A, Yap YS, Wang E, Gavathiotis E, Tsirigos A, Tibes R, Aifantis I. Chen X, et al. Among authors: yap ys. Cancer Discov. 2019 Jul;9(7):890-909. doi: 10.1158/2159-8290.CD-19-0117. Epub 2019 May 2. Cancer Discov. 2019. PMID: 31048321 Free PMC article.
Erratum: TET1 is a tumor suppressor of hematopoietic malignancy.
Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, Mullenders J, King B, Trimarchi T, Aranda-Orgilles B, Liu C, Shen S, Verma AK, Jaenisch R, Aifantis I. Cimmino L, et al. Among authors: yap ys. Nat Immunol. 2015 Aug;16(8):889. doi: 10.1038/ni0815-889a. Nat Immunol. 2015. PMID: 26194287 No abstract available.
Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2- advanced breast cancer.
Lu YS, Bin Mohd Mahidin EI, Azim H, Eralp Y, Yap YS, Im SA, Rihani J, Gokmen E, El Bastawisy A, Karadurmus N, Lim YN, Lim CS, Duc LT, Chung WP, Babu KG, Penkov K, Bowles J, Alfaro TD, Wu J, Gao M, Slimane K, El Saghir NS. Lu YS, et al. Among authors: yap ys. J Clin Oncol. 2024 May 21:JCO2400144. doi: 10.1200/JCO.24.00144. Online ahead of print. J Clin Oncol. 2024. PMID: 38771995
Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study.
Tan RYC, Ong WS, Lee KH, Park S, Iqbal J, Park YH, Lee JE, Yu JH, Lin CH, Lu YS, Ono M, Ueno T, Naito Y, Onishi T, Lim GH, Tan SM, Lee HB, Koh J, Han W, Im SA, Tan VKM, Phyu N, Wong FY, Tan PH, Yap YS. Tan RYC, et al. Among authors: yap ys. J Natl Compr Canc Netw. 2024 May 14:1-9. doi: 10.6004/jnccn.2023.7121. Online ahead of print. J Natl Compr Canc Netw. 2024. PMID: 38744306
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
Martín M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz FM, Safin R, Kim SB, Schem C, Montero AJ, Khan S, Bandyopadhyay R, Moore HM, Shivhare M, Patre M, Martinalbo J, Roncoroni L, Pérez-Moreno PD, Sohn J; acelERA Breast Cancer Study Investigators. Martín M, et al. J Clin Oncol. 2024 Mar 27:JCO2301500. doi: 10.1200/JCO.23.01500. Online ahead of print. J Clin Oncol. 2024. PMID: 38537155
127 results